Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tal & Tats, all good questions. My favorite is asking Denner Appleseed about broadening the R&D platform.
ForF'sSake is right. Caddie please chart a scatterplot of Tats' posting activity since his account creation date, and etch-a-sketch tangent lines to inform any further speculation into his posting activity. Otherwise, please drop the topic.
Thanks everyone.
Because iHub moves markets 🤣🤣🤣🤣😂😂😂😂
Whatever came of that FOIA request into PfDA trial data? Decisions accelerating a novel platform's first end-use requiring unprecedented supply chain logistics should be a nothing-burger...
Regulatory capture can sometimes be a form of financial engineering.
I also stop checking whether the deck is stacked, once I take a seat and start actually playing.
And it's all your fault
Or a medical device, like the Cope Button IT REELY CLEENS UP MUH BORD
Whereas you come here despite having something better to do?
MUH HANDS OF BEE PEE
I'm unsure whether he has complete or unfettered control of himself.
Why did you just quote urself?
Post more youtube crap gasbj
Tats
my guy
Golden parachute
Retention bonus
Severance package
8 minute performance review
9 month CVR
Don't be such a downer. Look at all the human capital he's generated!
That would be another reason to short it...
Would holding an underwater position while he says it be less odd, or more?
All the easy and much-deserved dunking on ragey aside, it's amazing to see how well-tuned IP protection drives improvements in population health.
Why does this make me think of R-It's CVR reduction somehow without lowering cholesterol?
Who holds the top 5 short positions against Amarin?
This board might as well be the Average Down Club
FFS isn't doom and gloom to spite you (that's AMRN pps's job)
To be fair, sometimes the FDA itself seems kinda... osteopathic
Complete change of topic, why would any Formularies want to drop coverage of a therapy proven to reduce costly CVR by ~25%?
Totally talking about something different here.
Gotta call shenanigans on this one. There's no way you're attempting that in front of your golfing buddies. Much less twice in a year.
It makes you wanna... you know.
Because, again, there is more to developing an invention than speculating about it in a science paper.